Daxor Announces Publication of Blood Volume Research Study By Vanderbilt University and National Institutes of Health Concerning Chronic Mountain Sickness Utilizing the BVA-100 Blood Volume Analyzer
Posted on: Friday, 17 March 2006, 09:00 CST
Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the publication of "Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia" in the 2006, 16th edition of the Journal of Autonomic Research. By using Daxor's blood volume analyzer, the study results determined that genetic, developmental, or adaptive changes are important to limit the response of the body to manipulate blood volume levels (plasma norepinephrine) responses to changes of oxygen levels.
The purpose of the study was to determine blood volume and hormone changes in subjects living in high altitudes who have chronic mountain sickness. This is a syndrome of maladaptation characterized by polycythemia (high red cell concentrations). More than 100 million people live and work in high altitude areas of the world, where people are subject to this condition. The study was conducted in Peru at high altitudes, and at sea levels. Test samples were collected and sent to the National Institutes of Health, where the actual blood volume measurements were made. The study, conducted by Dr. Alfredo Gamboa of Vanderbilt University Medical Center and Dr. David Goldstein of National Institutes of Health (NIH), in conjunction with Dr. Jorge Gamboa of Case Western Reserve University, and Dr. Courtney Holmes and Dr. Yehonatan Sharabi of the NIH, Dr. Fabiola Leon-Velarde of Universidad Peruana Cayetano Heredia, and Dr. Gary Fischman, Director of Research of Daxor Corporation. This study was supported in part by Daxor.
One of the key findings was that individuals who had chronic mountain sickness had an abnormal increase in their red cell volume while natives, who did not have this condition, had normal blood red cell volumes and increased plasma volumes. Removal of the excess red cell volume has been shown to improve the symptoms of some of the patients suffering from chronic mountain sickness. This is one of a number of studies where the Daxor Blood Volume Analyzer is currently being utilized for the diagnosis and treatment of blood volume derangements.
For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh, 212-330-8515 (VP of Operations) stephen@daxor.com or Diane Meegan, 212-330-8512 (Investor Relations) dmeegan@daxor.com.
Source: Business Wire
Related Articles
- Fenwal to Host Webinar on the Safety of 2-Unit Red Cell Collections From Young Donors
- Researchers Study How Glacial Erosion Changes Internal Mountain Structure
- International Stem Cell Corporation Announces Collaboration With Michigan State University to Study Parthenogenetic Stem Cells
- International Stem Cell Corporation Signs Agreement With BioTime, Inc., And Embryome Sciences, Inc., To Provide Unique Human Stem Cell Lines for Research Use
- International Stem Cell Corporation Announces Collaboration With the University of Cambridge to Study Parthenogenetic Stem Cells
- International Stem Cell Corporation Signs Letter of Intent With BioTime, Inc., And Embryome Sciences to Provide Unique Human Stem Cell Lines for Research Use
- International Stem Cell Corporation Creates Human Stem Cell Lines That Can Eliminate Immune Rejection By Patients
- BTHC III, Inc. (BTHC.OB) Changes Its Name and Stock Symbol to International Stem Cell Corporation (ISCO.OB)
- Cellerant Therapeutics Presents Positive Preclinical Data on Purified Blood-Forming Stem Cells at ASH
- Affymax Begins Clinical Trial of Hematide(TM) to Treat Anemia in Patients With Pure Red Cell Aplasia
 |
 |
User Comments (0)
RSS Feeds